ReviewCurrent drug targets2025
Assessing Anti-Acne Potentials
Review in Current drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advanced strategies to overcome multidrug resistance in cancer therapy: progress in P-glycoprotein inhibitors, drug delivery, and personalized medicine.Investigational new drugs · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acne vulgaris is the 8th most commonly prevailing skin disorder worldwide. Its pervasiveness has been predominant in juveniles, especially males, during adolescence and in females during adulthood. The lifestyle and nutrition adopted have been significantly reported to impact the occurrence and frequency of acne. It typically occurs over the regions of the forehead, upper chest, and back of the body, which are regions with high proportions of active sebaceous follicles. The market today is flooded with the pool of anti-acne medications (oral, topical/systemic) that contain either a single therapeutic agent or a blend targeting multiple pathological pathways. However, the clinical applicability of these preparations is limited due to formulation stability, drug penetrability, and targeting, the incidence of secondary effects, antibiotic resistance, etc. Moreover, the effectiveness of the former therapies varies as per the type and severity of acne. Therefore, it is necessary to extensively research skin physiology under normal and diseased conditions so that newer, safer, and more effective medications can be devised. Moreover, their safety and efficacy should be validated by employing various acne models, and their comparative profiling should be done with standard marketed anti-acne preparations. Acne models assist to uncover the complex disease pathogenesis and identify the potential targets for therapeutic interventions. This review is an attempt to highlight varied
Indexed as
Identifiers
39886785What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.